Mov Disord Vol 31, Suppl 2 Archives - Page 203 of 207 - MDS Abstracts

2016 International Congress
Is the selection of stepping impaired in PD in ON state?
C. Stummer, E. Mallia, J. Rothwell, B.R. Bloem, V. Weerdesteyn (Nijmegen, Netherlands)
Objective: To compare the selection of stepping actions during a probability reaction time task in people with Parkinson's disease (PD) in the ON state with…
2016 International Congress
Intraoperative localization of beta band and high-frequency oscillations within the subthalamic nucleus
B.C.M. van Wijk, A. Pogosyan, T. Foltynie, M.I. Hariz, P. Limousin, L. Zrinzo, P. Brown, V. Litvak (London, United Kingdom)
Objective: To investigate whether beta band activity (13-30Hz) and high-frequency oscillations (150-400Hz) arise from the same spatial location within the subthalamic nucleus (STN) of Parkinson's…
2016 International Congress
Detection of primary olfactory cortex dysfunction in early-stage Parkinson’s disease
J. Wang, T. Subramanian, Q.X. Yang (Hershey, PA, USA)
Objective: To detect the functional changes of primary olfactory cortex (POC) in the early-stage Parkinson's disease (PD) using functional magnetic resonance imaging (fMRI). Background: Olfactory…
2016 International Congress
Diagnosis and management of dementia with Lewy bodies: Influence of concomitant cerebrovascular disease
A. Chimagomedova, E. Vasenina, O. Levin (Moscow, Russia)
Objective: We assume that the cerebrovascular disease might influence on the course and clinical features of dementia with Lewy bodies (DLB). The aim of this…
2016 International Congress
Relationship of MDS-UPDRS non-motor symptoms to cognitive functioning in patients with Parkinson’s disease
B.A. Bernard, D. Carns, G.T. Stebbins, J.G. Goldman, C.G. Goetz (Chicago, IL, USA)
Objective: To evaluate the relationship among individual items from the MDS-UPDRS Part I and measures of cognitive functioning in patients with PD. Background: Non-motor symptoms…
2016 International Congress
Dopaminergic drug management in Parkinson’s disease: Gait and language function show correlation during treatment
H. Murakami, A. Futamura, T. Kuroda, S. Ishigaki, M. Kezuka, K. Ono, M. Kawamura (Tokyo, Japan)
Objective: We examined the effects of dopaminergic medication adjustment on cognitive function in Parkinson's disease (PD) patients without apparent dementia (Mini-Mental State Examination score of…
2016 International Congress
Investigating the relationship between reaction time and cognition in Parkinson’s disease
J. Cosgrove, C. Picardi, S.L. Smith, S. Jamieson, J.E. Alty (Leeds, United Kingdom)
Objective: To test the hypothesis that simple reaction time (SRT) is associated with global cognition in Parkinson's disease (PD) after controlling for motor function. Background:…
2016 International Congress
A technological solution for monitoring Parkinson’s disease: A patient-based perspective on necessity, usability and acceptability
S. Couth, E. Poliakoff, J. Vega, C. Jay, S. Harper, R. Almutiry, T.F. Cootes, A.M. Ramsay, S.A. Kotz (Manchester, United Kingdom)
Objective: The objectives of this study were twofold. First, to determine the feasibility of monitoring changes in how people with Parkinson's feel, think, and behave…
2016 International Congress
The effect of dopamine on global versus specific inhibitory control in Parkinson’s disease
D. Kuebler, H. Schroll, R. Eva, A. Diepold, C. Meyer, A. Kuhn (Berlin, Germany)
Objective: To evaluate the effect of dopaminergic medication on inhibitory control using a novel go/no-go task in Parkinson's disease (PD). Global cognition and motor examination…
2016 International Congress
Apolipoprotein E genotypes in Brazilian patients with Parkinson’s disease and their correlation with cognitive performance assessed by MoCA
M.M.C.M. Brito, R.S.J. Silva, V. Tumas, I.F. Mata, C.Z. Zabetian (Ribeirão Preto, Brazil)
Objective: Analysing the relationship between the polymorphisms of ApoE gene and cognitive performance of patients with Parkinson's disease. Background: Cognitive impairment is a common clinical…